Acral melanoma was found to have higher recurrence and lower survival rates than other types of melanoma and may require more aggressive surgical intervention, according to researchers.
MRV Research
3D melanoma model helps explain therapy evasion
Researchers at The University of Queensland Diamantina Institute and The University of Sydney Centenary Institute have developed a 3D model of a melanoma tumour that enables them to visualise the growth states of cancer cells in real-time. In a paper published in the journal Pigment Cell and Melanoma Research, they describe how they have used cutting-edge imaging technology to develop a 3D model that precisely measures cell cycles as a melanoma tumour grows.
Adjuvant ipilimumab improved RFS in high-risk, stage III melanoma
Adjuvant ipilimumab significantly improved RFS compared with placebo among patients with resected stage III melanoma who were at high risk for recurrence, according to the final analysis of a phase 3 study presented at the ASCO Annual Meeting.
Quest Diagnostics Introduces bioMerieux THxID®-BRAF Companion Diagnostic to Advance Precision Medicine for Melanoma
Quest Diagnostics , the world’s leading provider of diagnostic information services, today introduced a new cancer test service based on the FDA-approved THxID®-BRAF test from bioMerieux, a world leader in the field of in vitro diagnostics. The THxID®-BRAF test is a companion diagnostic for two treatments for melanoma. The test is intended to be used as an aid in selecting patients with melanoma whose tumors carry the BRAF V600E mutation for treatment with dabrafenib [Tafinlar®] and as an aid in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for treatment with trametinib